- Home
- CVRX vs ATXS Comparison
CVRX vs ATXS Comparison
Compare CVRX & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVRX
- ATXS
- Stock Information
- Founded
- CVRX 2000
- ATXS 2008
- Country
- CVRX United States
- ATXS United States
- Employees
- CVRX N/A
- ATXS N/A
- Industry
- CVRX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- CVRX Health Care
- ATXS Health Care
- Exchange
- CVRX Nasdaq
- ATXS Nasdaq
- Market Cap
- CVRX 419.8M
- ATXS 401.2M
- IPO Year
- CVRX 2021
- ATXS 2015
- Fundamental
- Price
- CVRX $12.23
- ATXS $5.34
- Analyst Decision
- CVRX Strong Buy
- ATXS Strong Buy
- Analyst Count
- CVRX 7
- ATXS 5
- Target Price
- CVRX $17.83
- ATXS $26.60
- AVG Volume (30 Days)
- CVRX 206.7K
- ATXS 276.5K
- Earning Date
- CVRX 04-29-2025
- ATXS 03-11-2025
- Dividend Yield
- CVRX N/A
- ATXS N/A
- EPS Growth
- CVRX N/A
- ATXS N/A
- EPS
- CVRX N/A
- ATXS N/A
- Revenue
- CVRX $51,292,000.00
- ATXS N/A
- Revenue This Year
- CVRX $27.21
- ATXS N/A
- Revenue Next Year
- CVRX $25.87
- ATXS N/A
- P/E Ratio
- CVRX N/A
- ATXS N/A
- Revenue Growth
- CVRX 30.53
- ATXS N/A
- 52 Week Low
- CVRX $6.40
- ATXS $5.29
- 52 Week High
- CVRX $19.24
- ATXS $14.04
- Technical
- Relative Strength Index (RSI)
- CVRX 44.32
- ATXS 28.85
- Support Level
- CVRX $11.80
- ATXS $5.89
- Resistance Level
- CVRX $12.94
- ATXS $6.52
- Average True Range (ATR)
- CVRX 0.56
- ATXS 0.40
- MACD
- CVRX 0.17
- ATXS -0.06
- Stochastic Oscillator
- CVRX 53.94
- ATXS 2.50
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.